NCT04106557 - A Study of OV101 in Individuals With Angelman Syndrome (AS) | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

September 9, 2019

Primary Completion Date

November 2, 2020

Study Completion Date

November 2, 2020

Conditions

Primary Disease or Condition Being Studied: Angelman Syndrome (AS)

Interventions

DRUG

Gaboxadol

OV101 versus placebo once daily at bedtime for 12 weeks

DRUG

Placebo

Matching placebo capsules to OV101 capsules.

Trial Locations (14)

Ovid Therapeutics Investigative Site, Heidelberg

Ovid Therapeutics Investigative Site, Brisbane

Ovid Therapeutics Investigative Site, Media

Ovid Therapeutics Investigative Site, Nashville

Ovid Therapeutics Investigative Site, Cincinnati

Ovid Therapeutics Investigative Site, Ramat Gan

Ovid Therapeutics Investigative Site, Chicago

Ovid Therapeutics Investigative Site, Munich

Ovid Therapeutics Investigative Site, Phoenix

Ovid Therapeutics Investigative Site, Tacoma

Ovid Therapeutics Investigative Site, San Diego

Ovid Therapeutics Investigative Site, Boston

Ovid Therapeutics Investigative Site, Lexington

Ovid Therapeutics Investigative Site, Rotterdam